Abstract LB262: Development of a clinically feasible aqueous proteomic signature to assess the malignant potential of small uveal melanocytic tumors

Olga Zolochevska; Julia Litvinov; Kyle R. Covington; David A. Reichstein; Amy C. Schefler; Zelia M. Correa; Jason Maarsing; Kasia Wozny; Katherina M. Alsina

doi:10.1158/1538-7445.AM2025-LB262

Back

Abstract LB262: Development of a clinically feasible aqueous proteomic signature to assess the malignant potential of small uveal melanocytic tumors

Journal article

Peer reviewed

Abstract LB262: Development of a clinically feasible aqueous proteomic signature to assess the malignant potential of small uveal melanocytic tumors

Olga Zolochevska, Julia Litvinov, Kyle R. Covington, David A. Reichstein, Amy C. Schefler, Zelia M. Correa, Jason Maarsing, Kasia Wozny and Katherina M. Alsina

Cancer research (Chicago, Ill.), Vol.85(8_Supplement_2), pp.LB262-LB262

2025-04-25

DOI: https://doi.org/10.1158/1538-7445.AM2025-LB262

Appears in Miller School of Medicine - Latest Publications

Metrics

8 Record Views

Details

Title: Abstract LB262: Development of a clinically feasible aqueous proteomic signature to assess the malignant potential of small uveal melanocytic tumors
Creators: Olga Zolochevska
Julia Litvinov
Kyle R. Covington
David A. Reichstein - Tennessee Retina
Amy C. Schefler - Retina Consultants of Houston
Zelia M. Correa - University of Miami
Jason Maarsing
Kasia Wozny
Katherina M. Alsina
Publication Details: Cancer research (Chicago, Ill.), Vol.85(8_Supplement_2), pp.LB262-LB262
Academic Unit: UMMG Department of Ophthalmology; Miller School of Medicine
Language: English
Resource Type: Journal article
Record Identifier: 991032662117802976